US opioid market to hit $17.7 billion by 2021, says GBI Research
31 March 2016 | By Victoria White
The US market for opioids will grow from $11 billion in 2014 to $17.7 billion by 2021, according to business intelligence provider GBI Research...
List view / Grid view
News
Lilly and Incyte announce results from RA-BEACON baricitinib study
Lilly and Incyte have announced results from the RA-BEACON Phase III study of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA).
FDA grants orphan drug designation to Iomab-B
31 March 2016 | By Victoria White
Actinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant...
Children with cancer to be offered gene testing in personalised treatment initiative
31 March 2016 | By Victoria White
Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment...
NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)
30 March 2016 | By Victoria White
Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1...
BPL’s Coagadex approved in the EU for hereditary factor X deficiency
30 March 2016 | By Victoria White
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency...
DiscoverX launches KILR™ assay platform for use in cancer immunotherapy drug development
30 March 2016 | By DiscoverX Corporation
DiscoverX Corporation has launched the KILR Retroparticles product line, providing scientists complete flexibility to develop a simple cytotoxicity assay in almost any cell line...
Inovio’s Ebola vaccine generates robust immune responses in humans
30 March 2016 | By Victoria White
Inovio’s Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its Phase I study of 75 healthy subjects...
Coulter Partners appoints Laura Esam as London Director
30 March 2016 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners, have appointed Laura Esam as Director in their London office...
AcelRx appoints Howard B. Rosen as CEO; focuses on ARX-04
30 March 2016 | By Victoria White
Howard B. Rosen has been appointed the Chief Executive Officer of AcelRx. The company has also selected ARX-04 as its primary focus for clinical development...
First patient recruited in IMCgp100 uveal melanoma trial
30 March 2016 | By Victoria White
The trial of IMCgp100 will include three Phase I escalation cohorts to determine the optimal dose for the Phase II study, which is expected to start in 2016...
Celyad posts an update on its NKR-2 Trial
30 March 2016 | By Victoria White
Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...
Shire wins Lialda patent trial against Watson
29 March 2016 | By Victoria White
The US District Court for Southern Florida has upheld Shire's patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis...
ECCMID late-breaking sessions to focus on colistin resistance and migrant health
29 March 2016 | By Victoria White
A total of 340 late-breaker abstracts have been submitted to ECCMID: 25 are related to refugee health, 44 to colistin resistance, and 271 on other topics...
First patient recruited in Visco-ease RIX study
29 March 2016 | By Victoria White
The study will assess Visco-ease’s ability to restore the function of saliva in patients undergoing radiotherapy for the treatment of Head and Neck Cancer...
